PL392702A1 - Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna - Google Patents

Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna

Info

Publication number
PL392702A1
PL392702A1 PL392702A PL39270210A PL392702A1 PL 392702 A1 PL392702 A1 PL 392702A1 PL 392702 A PL392702 A PL 392702A PL 39270210 A PL39270210 A PL 39270210A PL 392702 A1 PL392702 A1 PL 392702A1
Authority
PL
Poland
Prior art keywords
nucleotide
nucleotide analog
analog
pharmaceutical composition
pro
Prior art date
Application number
PL392702A
Other languages
English (en)
Other versions
PL217694B1 (pl
Inventor
Adam Kraszewski
Joanna Romanowska
Agnieszka Szymańska-Michalak
Michał Sobkowski
Jerzy Boryski
Jacek Stawiński
Andrzej Lipniacki
Andrzej Piasek
Original Assignee
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Narodowy Instytut Leków
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Chemii Bioorganicznej Polskiej Akademii Nauk, Narodowy Instytut Leków filed Critical Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority to PL392702A priority Critical patent/PL217694B1/pl
Priority to PCT/PL2011/000103 priority patent/WO2012053917A1/en
Priority to US13/879,709 priority patent/US9206209B2/en
Priority to EP11781885.6A priority patent/EP2630152B1/en
Publication of PL392702A1 publication Critical patent/PL392702A1/pl
Publication of PL217694B1 publication Critical patent/PL217694B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy oraz kompozycja farmaceutyczna. Bardziej dokładnie wynalazek dotyczy nowej grupy pochodnych nukleotydowych oraz ich zastosowania w częściowym lub całkowitym hamowaniu namnażania ludzkiego wirusa niedoboru odporności (HIV).
PL392702A 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna PL217694B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL392702A PL217694B1 (pl) 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna
PCT/PL2011/000103 WO2012053917A1 (en) 2010-10-19 2011-10-13 Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
US13/879,709 US9206209B2 (en) 2010-10-19 2011-10-13 Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
EP11781885.6A EP2630152B1 (en) 2010-10-19 2011-10-13 Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL392702A PL217694B1 (pl) 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna

Publications (2)

Publication Number Publication Date
PL392702A1 true PL392702A1 (pl) 2012-04-23
PL217694B1 PL217694B1 (pl) 2014-08-29

Family

ID=44936505

Family Applications (1)

Application Number Title Priority Date Filing Date
PL392702A PL217694B1 (pl) 2010-10-19 2010-10-19 Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna

Country Status (4)

Country Link
US (1) US9206209B2 (pl)
EP (1) EP2630152B1 (pl)
PL (1) PL217694B1 (pl)
WO (1) WO2012053917A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL238768B1 (pl) * 2017-07-31 2021-10-04 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Nowy analog nukleozydo difosforanu, kompozycja farmaceutyczna zawierająca analog nukleozydo difosforanu, jego zastosowanie i sposób syntezy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
CN1133642C (zh) 2000-10-09 2004-01-07 清华大学 核苷5’-硫代磷酰氨基酸酯化合物
RU2243972C1 (ru) 2003-06-26 2005-01-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Фосфорамидаты нуклеозидных аналогов - ингибиторы репродукции вируса иммунодефицита человека
CA2618335C (en) 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
CN102099367A (zh) 2007-01-17 2011-06-15 蒙特利尔临床研究所 具有季碳中心的核苷和核苷酸类似物以及其使用方法
WO2008118879A2 (en) 2007-03-23 2008-10-02 Ardea Biosciences, Inc. Antiviral compositions comprising 2 compounds

Also Published As

Publication number Publication date
EP2630152B1 (en) 2014-11-26
EP2630152A1 (en) 2013-08-28
US20130316970A1 (en) 2013-11-28
WO2012053917A1 (en) 2012-04-26
US9206209B2 (en) 2015-12-08
PL217694B1 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
CY1121452T1 (el) Παραγωγα πουρινης για τη θεραπευτικη αντιμετωπιση ιικων λοιμωξεων
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MX2009013349A (es) Compuestos quimicos.
MD20200093A2 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
PH12015501156A1 (en) Pharmaceutical compositions
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2555798A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
WO2012047267A3 (en) Polyvalent immunogen
MX360161B (es) Proceso para preparar compuestos antiviricos.
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2012139097A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
GB2463584A (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
PL392702A1 (pl) Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna
MX2013003551A (es) Formas en estado solido de un potente inhibidor del vch.